作者: Daniel A. Arber , Olga K. Weinberg
DOI: 10.1007/S11912-021-01060-8
关键词:
摘要: Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique subset. The 2016 WHO classification includes more clear restrictive diagnostic criteria for AEL. Primary erythroid associated with complex high-risk karyotypes including chromosomes 5q 7q abnormalities. Mutational data shows that AEL characterized far lower NPM1 FLT3-ITD mutation rates higher mutational in TP53 compared other AML subtypes. Hypomethylating agents have shown value In article, we discuss the evolving concepts erythroleukemia, genomics, clinical outcome, promising targets through an appraisal current literature.